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Abstract
The concentration of circulating heat shock protein 70 (Hsp70) was measured in liquid biopsies of canine tumor patients as a
potential biomarker. Compared with rodent tumor models, spontaneously occurring tumors in pet dogs reflect the clinical
situation of human patients better, as dogs cohabitate with their owners in the same environment, reach a much older age than
rodents, can provide blood samples much more frequently, and receive up-to-date medical care and, similar to humans, their
tumors show a high genetic heterogeneity. Due to the species-specific sequence homology of human and canine Hsp70, two
human enzyme-linked immunosorbent assay (ELISA) systems (R&D and lipHsp70) were used to measure canine Hsp70
concentrations in serum and plasma. In general, higher Hsp70 concentrations were found in serum compared with plasma
samples of dogs, and the lipHsp70 ELISA detected higher peak concentrations of Hsp70 in a broader range than the R&D
ELISA. Compared with a tumor-free control group, serumHsp70 concentrations were higher in tumor-bearing dogs, irrespective
of breed, age, body weight, and gender. A sub-classification of the different tumors according to their cytological characteristics
revealed significantly elevated Hsp70 serum concentrations in dogs with round cell tumors (p < 0.01), a heterogeneous group of
malignancies with hematopoietic origin such as mast cells, plasma cells, lymphocytes, histiocytes, and melanomas. Future
studies with larger patient cohorts and well-defined tumor sizes are necessary to elucidate the role of serumHsp70 as a biomarker
for tumor detection and monitoring of outcome in pet animals.
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Introduction
Members of the different heat shock protein (HSP) families
are highly conserved in evolution with a high sequence
homology among different species (Hartl 1996; Daugaard
et al. 2007; Shalgi et al. 2014). According to their molecular
weights, HSPs are subdivided into large (HSP110, HSP90,
HSP70, HSP60) and small (HSP10, HSP25, HSP27) families
(Horvath et al. 2008). Themajor stress-inducible Hsp70with a
molecular weight of approximately 70 kDa forms
multichaperone complexes together with Hsp40 and Hsp90
and the co-chaperones HiP and HoP (Wegele et al. 2004;
Qiu et al. 2006). In contrast to most proteins whose expression
is downregulated upon stress, the synthesis of HSPs, and es-
pecially that of Hsp70, is highly upregulated (Daugaard et al.
2007). Apart from heat stress, a large variety of other physical
and chemical stress stimuli, as well as physiological processes
such as proliferation, differentiation, and antigen presentation,
can also trigger the synthesis of HSPs (Lindquist and Craig
1988; Hartl 1996; Whitley et al. 1999). Following the trans-
location of the trimerized heat shock factor into the nucleus
and binding to the heat shock element in the promotor region,
the expression of HSPs is induced (Akerfelt et al. 2010).
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Members of the HSP70 family are found in nearly all sub-
cellular compartments, including the cytosol, nucleus, endo-
plasmic reticulum, mitochondria, lysosomes, and endosomes
(Radons and Multhoff 2005). As molecular chaperones, intra-
cellular HSP70s are involved in the correct folding of unfold-
ed proteins, proteasomal degradation, transport across mem-
branes (Ostermann et al. 1990), prevention of protein aggre-
gation, apoptosis after stress, and cell cycle regulation (Hunt
and Morimoto 1985; Lindquist and Craig 1988; Hartl 1996;
Selvarajah et al. 2013).
It is well established that, compared with normal cells,
tumor cells overexpress Hsp70 even under non-stress condi-
tions (Hantschel et al. 2000; Ciocca and Calderwood 2005;
Rohde et al. 2005). Although Hsp70 is primarily a cytosolic
protein, our group was the first to demonstrate membrane
localization of Hsp70 on a large variety of human and mouse
tumor cell types (Hantschel et al. 2000; Multhoff et al. 1995;
Stangl et al. 2011). Moreover, membrane Hsp70-positive tu-
mor cells have been found to actively release Hsp70 in lipid
microvesicles (Cordonnier et al. 2017) with molecular charac-
teristics of exosomes (Gastpar et al. 2005). Free Hsp70 orig-
inating from dying cells and exosomal Hsp70 which is active-
ly released by viable tumor cells can be quantified in the blood
of patients with tumors by using the novel lipHsp70 ELISA
(Breuninger et al. 2014). This ELISA is based on the
cmHsp70.1 mouse IgG1 monoclonal antibody (mAb) detect-
ing an 8-mer epitope of Hsp70 in the C-terminal oligomeriza-
tion domain that is exposed on the surface of tumor cells and
tumor-derived exosomes (Stangl et al. 2011; Breuninger et al.
2014). Consequently, elevated Hsp70 serum and plasma
levels could be correlated with the viable tumor mass in pa-
tients with non-small cell lung carcinoma (NSCLC) before
and after radiochemotherapy (Gunther et al. 2015).
In the present study, we addressed the question whether
circulating exosomal Hsp70 determined by the lipHsp70
ELISA could also provide a useful tumor biomarker in liquid
biopsies for companion animals. In pet dogs, elevated intra-
cellular Hsp70 levels were reported in osteosarcoma (Asling
et al . 2016), mammary (Romanucci et al . 2006;
Kumaraguruparan et al. 2006), and transmissible venereal tu-
mors (Chu et al. 2001), as determined by Western blot analy-
sis, and immunohistochemical staining. Herein, we examined
Hsp70 plasma and serum levels in dogs with different tumors
and in tumor-free control animals. According to their cytolog-
ical characteristics, tumors in dogs were classified in three
main groups: mesenchymal, epithelial, and round cell
(Withrow et al. 2012; Villiers et al. 2016; Raskin and Meyer
2016). Canine tumors derived from the mesenchyme com-
prise degenerations of osseous and soft tissues, different types
of sarcoma, and neoplasms of blood vessels. Tumors of epi-
thelial origin included cancers of glands and epithelial sur-
faces such as the skin, respiratory, and gastrointestinal tract.
Canine round cell tumors mainly consist of tumors of
hematopoietic origin such as mast cells, plasma cells, lympho-
cytes, and histiocytes and also include melanomas according
to their cytological classification (Raskin and Meyer 2016).
Material and methods
Cell culture of canine tumor cell lines
Two canine tumor cell lines (K9STS, mesenchymal tumor;
K9MM2, round cell tumor) derived from primary tumors
were kindly provided by Professor Dr. Rohrer Bley. K9STS
cells were cultured at 37 °C under 5% CO2 in a humidified
atmosphere in RPMI 1640 medium (R8758, Sigma Aldrich,
St. Louis, MO, USA) supplemented with 10% FCS (F7524,
Sigma Aldrich, St. Louis, MO, USA), 1% HEPES (15630-
056, Gibco, Thermo Scientific, Rockford, IL, USA), 1% L-
glutamine (G7513, Sigma Aldrich, St. Louis, MO, USA), 1%
MEM non-essential amino acid (NEAA) (11140-050, Gibco,
Thermo Scientific, Rockford, IL, USA), 1% sodium pyruvate
(S8636, Sigma Aldrich, St. Louis, MO, USA), and 1%
penicillin-streptomycin (P0781, Sigma Aldrich, St. Louis,
MO, USA). K9MM2 cells were cultured in high glucose
Dulbecco’s Modified Eagle Medium (DMEM) (D6429,
Sigma Aldrich, St. Louis, MO, USA) supplemented with
10% FCS, 1% HEPES, and 1% penicillin-streptomycin at
37 °C under 5% CO2 in a humidified atmosphere. Cells were
regularly passaged every second day and used for experiments
in the exponential growth phase. Cell lines were tested nega-
tive for mycoplasma contamination.
Western blot
K9STS and K9MM2 cells (2 × 106) were lysed in
radioimmunoprecipitation assay (RIPA) buffer for 20 min on
ice after washing three times in PBS. Cell lysates were centri-
fuged at 12,000g for 20 min at 4 °C, and supernatant was
transferred into Eppendorf tubes. Protein concentrations were
determined using the BCA Protein Assay Kit (23225, Pierce,
Thermo Scientific, Rockford, IL, USA). Thirty micrograms of
cytosolic protein from each cell line was loaded on a 10%
SDS-PAGE. Human recombinant Hsp70 protein (32.5 ng)
was used as an internal control.
A nitrocellulose membrane (10600002, GE Healthcare,
Wauwatosa, WI, USA) was used for blotting. Membranes
were blocked using 5% skim milk in TBST for 1 h at room
temperature. Primary antibodies, anti-Hsp70: cmHsp70.1
(multimmune, Munich, Germany, 1:1000), and anti ß-actin:
A2228 (Sigma Aldrich, St. Louis, MO, USA; 1:10000) were
diluted in 5% skim milk/TBST and incubated at 4 °C over-
night. Membranes were washed three times with TBST. The
secondary, horseradish-peroxidase (HRP)–conjugated anti-
body (P0260, Dako, Agilent, Santa Clara, CA, USA) was
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diluted 1:1,000 in 5% skim milk/TBST and incubated for 1 h
at room temperature. Membranes were washed three times for
15min at room temperature using TBSTand subjected to ECL
Western blotting substrate (32106, Pierce, Thermo Scientific,
Rockford, IL, USA) for 30 s in the dark before exposure
(1708370, ChemiDoc Touch Imaging System, Biorad
Laboratories, Hercules, CA, USA).
lipHsp70 ELISA
For measuring the Hsp70 content in canine plasma and serum
samples, the lipHsp70 ELISA that was established for human
blood samples to quantify free and liposomal Hsp70 in the
circulation was used. For the lipHsp70 ELISA, 96-well
MaxiSorp Nunc-Immuno plates (442404, Thermo,
Rochester, NY, USA) were coated overnight at room temper-
ature with 2 μg/ml rabbit polyclonal antibody (Davids,
Biotechnologie, Regensburg, Germany) directed against hu-
man recombinant Hsp70 in sodium carbonate buffer (0.1 M
sodium carbonate, 0.1 M sodium hydrogen carbonate, pH
9.6). After washing three times with PBS (D8537, Sigma
Aldrich, St. Louis, MO, USA)/0.05% Tween-20 (655205,
Merck, Darmstadt, Germany), the assay was blocked with
2% skim milk (T145.2, Carl Roth, Karlsruhe, Germany) in
PBS for 1.5 h at 27 °C. A dilution of 1:5 of the canine samples
in CrossDown Buffer (A6485, Applichem, Darmstadt,
Germany) appeared to be optimal for the ELISA assay.
Following another washing step, 100 μl of the diluted samples
was added to the wells for 2 h at 27 °C. Then, the plates were
washed in PBS and incubated with 3 μg/ml biotinylated
mouse anti-human cmHsp70.1 mAb (multimmune, Munich,
Germany) in 2% skim milk in PBS for 2 h at 27 °C. Finally,
after another washing step, 0.2 μg/ml HRP-conjugated
streptavidin (DRG, Marburg, Germany) in 1% bovine serum
albumin (A7030, Sigma Aldrich, St. Louis, MO, USA) was
added for 1 hat 27 °C. Binding was quantified by adding the
substrate reagent (DYC1663E, R&D Systems, Minneapolis,
MN, USA) for 30min at 27 °C. The absorbancewas measured
at a wavelength of 450 nm, corrected by the absorbance at
570 nm using a Microplate Reader (ELx800, BioTek,
Winooski, VT, USA). A standard curve using eight concen-
trations of recombinant Hsp70, ranging from 0 to 50 ng/ml
diluted in CrossDown Buffer, was included in each ELISA
test. The blank was determined by measuring the absorbance
of PBS diluted 1:5 in CrossDown Buffer. For all concentra-
tions below the established limit of detection of 0.31 ng/ml
(Breuninger et al. 2014) measured with lipHsp70 ELISA,
0.31 ng/ml was valued in statistical analysis.
R&D systems Hsp70 ELISA
As a control, all serum samples were also measured with the
commercial DuoSet® IC Human/Mouse/Rat total Hsp70
ELISA (DYC1663E, R&D Systems, Minneapolis, MN,
USA). The DuoSet IC Human/Mouse/Rat total Hsp70
ELISAwas applied following the manufacturer’s instructions.
Statistics
For each individual animal, Hsp70 was tested in at least three
experiments (maximum 12 experiments). Mean values of all
evaluable values were calculated for each individual animal
and those mean values were considered for statistical analysis.
For animals that had no single measure above the minimum
detection level, the value 0.31 ng/ml was used. As distribution
of Hsp70 data were skewed, median values and quartiles are
presented as median (1st quartile–3rd quartile). For compari-
son of independent samples, Wilcoxon rank-sum tests were
performed. The Wilcoxon signed-rank test was used to com-
pare paired data. For the receiver operating characteristics
(ROC) analyses, assessing whether Hsp70 levels can be used
to discriminate healthy from diseased dogs, only healthy ani-
mals and animals suffering from disease of interest were in-
cluded. For each analysis, the area under the ROC curve
(AUC), the Hsp70 cut-off value giving the highest sum of
sensitivity and specificity, and the corresponding sensitivity
and specificity are presented. All statistical tests were per-
formed two-sided and a significance level of α = 5% was
used.
Results
cmHsp70.1 monoclonal antibody detected canine
Hsp70
Recently, our group has developed the lipHsp70 ELISA to
quantify liposomal and free Hsp70 in serum and plasma of
human donors (Breuninger et al. 2014). By comparing Hsp70
levels of patients with tumors with an age- and gender-
matched control cohort, we demonstrated that patients with
tumors revealed significantly higher Hsp70 concentrations in
the blood than healthy human volunteers. Herein, we ad-
dressed whether the lipHsp70 ELISA could be used to detect
Hsp70 in the serum and plasma of pet dogs with spontaneous
tumors.
As mentioned above, the Hsp70 protein is highly con-
served across different species, including humans, mice, rats,
and dogs. A comparison of the 8-mer epitope (N-L-L-G-R-F-
E-L) that is recognized by the cmHsp70.1 mAb (Stangl et al.
2011) showed that this protein sequence is identical in human
and canine Hsp70 (UniProt database: human Hsp70:
P0DMV8, canine Hsp70: Q7YQC6). Furthermore, Western
blot analysis of cell lysates in canine soft tissue sarcoma
(K9STS, mesenchymal tumor) and malignant melanoma
(K9MM2, round cell tumor) revealed a specific band at
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72 kDa using cmHsp70.1 antibody (Fig. 1). The 43-kDa ß-
actin band served as a loading control (Fig. 1), and human
recombinant Hsp70 protein was subjected as a molecular
weight control (Fig. 1). These data indicated that cmHsp70.1
mAb is able to detect human as well as canine Hsp70.
Hsp70 serum levels were higher in canine serum
compared with plasma
To determine whether Hsp70 could be detected in canine
blood using the human lipHsp70 ELISA, serum (S) and plas-
ma (P) samples were collected from healthy control (S: n = 38,
P: n = 25) and tumor-bearing dogs (S: n = 74, P: n = 42). The
study was carried out in strict accordance with the recommen-
dations and the protocol approved by the Animal Ethics
Council of the Canton Zurich, Switzerland and the Ludwig-
Maximilians University Munich, Germany.
Serum and plasma samples were measured with the
lipHsp70 ELISA using the protocol established for human
blood samples (Breuninger et al. 2014). As Fig. 2 shows,
Hsp70 concentrations were higher in serum and plasma sam-
ples of canines with tumors (median S: 1.98 (0.84–6.26)
ng/ml; median P: 0.43 (0.31–1.08) ng/ml) compared with
healthy control animals (median S: 1.43 (0.68–2.97) ng/ml;
median P: 0.31 (0.31–0.40) ng/ml). In contrast to human sam-
ples, Hsp70 values were significantly higher in serum com-
pared with plasma samples in both animal groups (p < 0.001)
(Fig. 2).
In human serum and plasma samples, the cmHsp70.1 mAb
used as a detection antibody in the lipHsp70 ELISA, detects
free and lipid-bound exosomal Hsp70, which was actively
released by viable tumor cells (Stangl et al. 2011; Gastpar
et al. 2005). Therefore, the lipHsp70 ELISA detected higher
Hsp70 concentrations in the blood of humans than the com-
mercially available R&D ELISA. In canine serum samples,
the range of the Hsp70 concentrations in control (median lip
control: 1.43 (0.68–2.97) ng/ml) and tumor-bearing animals
(median lip tumor-bearing: 1.98 (0.84–6.26) ng/ml) measured
with the lipHsp70 ELISAwas larger than that measured with
the R&D ELISA (median R&D control: 1.57 (1.20–2.02)
ng/ml; median R&D tumor-bearing: 2.12 (1.55–3.18) ng/ml
(Fig. 3).
Food intake and up to three freezing/thawing cycles
did not affect Hsp70 serum levels in dogs
Potential effects of external interference factors that could im-
pact Hsp70 serum levels of dogs were assessed. Food intake
and repeated freezing/thawing cycles of the serum samples
were tested regarding the detection of free and lipid-bound
Fig. 1 Western blot analysis of cell lysates of canine soft tissue sarcoma
(K9STS) and malignant melanoma (K9MM2). Lane 1: cell lysate of
K9STS. Lane 2: cell lysate of K9MM2 cells (30 μg protein each). Lane
3: human recombinant Hsp70 (32.5 ng) as a positive control. ß-Actin
served as a loading control
Fig. 2 Comparison of the Hsp70 concentrations in serum and plasma as
determined by the lipHsp70 ELISA. Serum (S: n = 112) and plasma (P:
n = 67) samples were taken from healthy control (S: n = 38; P: n = 25) and
tumor-bearing (S: n = 74; P: n = 42) pet dogs. Lines inside the box plots
show the median value, upper and lower boundaries indicate the 25th and
75th percentile, and whiskers indicate highest and lowest value within 1.5
IQR, respectively. Not all outliers are shown. ***p < 0.001
Fig. 3 Comparison of the Hsp70 concentrations in serum as determined
by the lipHsp70 and R&D ELISA. Serum samples of 38 healthy and 74
tumor-bearing canines were measured with lipHsp70 ELISA in quadru-
plicates and with R&D ELISA in duplicates. Lines inside the box plots
show the median value, upper and lower boundaries indicate the 25th and
75th percentile, and whiskers indicate highest and lowest value within 1.5
IQR, respectively. Not all outliers are shown
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Hsp70 by the lipHsp70 ELISA. Serum was collected from
healthy dogs that differed in their basal Hsp70 concentrations
(dog 1: 0.8 ng/ml; dog 2: 3.3 ng/ml; dog 3: 0.5 ng/ml) before
and 2 h after intake of a high-fat diet. The quantity of given
food was adjusted to the metabolic body mass of each animal
to ensure that the calorie intake per kilogram metabolic
bodyweight was identical for each animal. The amount of
food was equal to one-third of each dog’s daily food ration.
As Fig. 4a shows, food intake did not influence the Hsp70
serum levels within the given time period. Another test was
performed to study the influence of repeated freezing/thawing
of the serum samples on the Hsp70 content that was detectable
by the lipHsp70 ELISA. Serum samples of dogs that differed
in their basal Hsp70 serum concentrations (dog 1: 1.5 ng/ml;
dog 2: 7.9 ng/ml; dog 3: 3.5 ng/ml) were subjected to eight
repeated freezing/thawing cycles, and Hsp70 concentrations
were measured after each cycle. Our results revealed that
Hsp70 concentrations measured by the lipHsp70 ELISA
remained almost stable for up to three repeated freezing/
thawing cycles (Fig. 4b); however, thereafter, a drop of the
Hsp70 concentrations was detectable in all analyzed samples
(data not shown).
Hsp70 serum levels were significantly elevated
in dogs with round cell tumors
As Table 1 summarizes, the control group consisted of 38
healthy dogs of different ages and breeds. The animals were
admitted to the veterinary clinic for routine examinations and
procedures such as vaccination, hip X-ray, or sterilization.
None of the animals showed any signs of infection or inflam-
mation at the time of blood collection. Hsp70 serum levels did
not show any correlation with age, weight, gender, breed, and
sterilization status of the dogs (data not shown).
The tumor cohort consisted of 74 animals with cytological
and histopathological confirmed neoplastic diseases. All
Fig. 4 Influence of external interference factors on Hsp70 serum
concentrations as determined by the lipHsp70 ELISA. a Serum samples
were taken from three healthy dogs with a different Hsp70 concentrations
before (gray) and 2 h after intake (black bars) of a high-fat diet.
Determination of Hsp70 concentrations revealed no significant differ-
ences before and after food intake for each dog. b Serum of both control
and tumor-bearing dogs was subjected to up to eight freezing/thawing
cycles (only the first four cycles shown). The Hsp70 concentration was
determined after each cycle using the lipHsp70 ELISA. Levels remained
nearly unchanged until the third freezing/thawing cycle. Thereafter, a
drop in the Hsp70 concentrations was detectable (data not shown)
Table 1 Breed, age, weight, and gender of healthy control dogs
No. Breed Age Weight (kg) Gender
1 Cross-breed 2 16 Female
2 French Bulldog 8 10 Female
3 Labrador Retriever 2 27 Male
4 Irish Terrier 6 15 Female
5 German Shepherd 2 38 Male
6 Australian Cattle 5 20 Male
7 Cross-breed 12 15 Female
8 Hovawart 8 43 Male
9 Golden Retriever 5 30 Male
10 Beagle 3 12 Male
11 Siberian Husky 1 14 Female
12 Labrador Retriever 5 32 Male
13 Labrador Retriever 9 37 Male
14 Chihuahua 9 3 Female
15 Flat-coated Retriever 8 33 Female
16 Labrador Retriever 10 35 Male
17 Beagle 4 13 Female
18 Beagle 4 12 Female
19 Beagle 4 12 Female
20 Flat-coated Retriever 6 33 Male
21 Cross-breed 14 8 Female
22 Dalmatian 5 27 Male
23 Cross-breed 4 20 Female
24 Cross-breed 8 32 Male
25 Flat-coated Retriever 8 28 Female
26 Flat-coated Retriever 5 28 Female
27 Flat-coated Retriever 1 30 Female
28 Beagle 4 17 Male
29 Beagle 4 17 Female
30 Small Munsterlander 5 17 Female
31 Dachshund 10 8 Female
32 Rottweiler 1 38 Female
33 Cross-breed 12 21 Male
34 Nova Scotia Duck Tolling Retriever 1 19 Male
35 Jack Russell Terrier 9 9 Male
36 Lagotto Romagnolo 2 14 Female
37 French Bulldog 8 10 Male
38 German Shepherd 5 30 Male
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tumors spontaneously occurred, and all dogs lived in a non-
sterile environment.
According to their cytological characteristics (Tables 2, 3,
and 4), the tumors could be sub-classified as mesenchymal,
epithelial, and round cell. Hsp70 serum concentration was
measured in healthy dogs (n = 38) and canines with mesen-
chymal (n = 27), epithelial (n = 22), and round cell tumors
(n = 25) using the lipHsp70 and R&D ELISA. As Fig. 5
shows, the Hsp70 serum concentrations of dogs with round
cell tumors were significantly higher (median lip: 4.37 (1.44–
14.32) ng/ml; median R&D: 2.55 (1.89–5.28) ng/ml) com-
pared with the control group (median lip: 1.43 (0.68–2.97)
ng/ml; median R&D: 1.57 (1.20–2.02) ng/ml) (p < 0.01)
(Fig. 5a, b). In contrast, the concentrations of Hsp70 in dogs
with mesenchymal (median lip: 1.57 (0.56–3.55) ng/ml; me-
dian R&D: 1.90 (1.59–2.77) ng/ml) and epithelial tumors
(median lip: 1.11 (0.52–4.18) ng/ml; median R&D: 1.83
(1.21–2.62) ng/ml) were not significantly different to that of
healthy animals (Fig. 5a, b).
To investigate potential variations in serum Hsp70 concen-
trations that might depend on the time of the admission of the
dog to the clinic, serum samples of dogs with round cell tu-
mors were collected over a time period of 2 years. Hsp70
serum concentrations of dogs with round cell tumors collected
in the first year (median cohort 1: 4.18 (1.33–14.26) ng/ml)
did not differ significantly in their distribution from samples
collected in the second year (median cohort 2: 6.97 (2.35–
26.99) ng/ml). The values of both cohorts differed significant-
ly from those of control animals (median: 1.43 (0.68–2.97)
ng/ml).
The ROC analysis comparing the round cell tumor group
with healthy dogs provided an AUC of 72%. A cut-off value
of 2.33 ng/ml (sensitivity 64%, specificity 66%) was used as a
threshold for Hsp70 serum content as a possible tumor bio-
marker in canine round cell tumors. A further subgroup anal-
ysis of dogs with round cell tumors revealed that canine pa-
tients with mast cell tumors had significantly higher Hsp70
serum concentration (median: 4.18 (1.71–9.26) ng/ml)
Table 2 Characteristics of dogs diagnosed with mesenchymal tumors
# Diagnosis Tumor location Extension Breed Age Weight (kg) Gender
1 Hemangiopericytoma Tarsus Local Cross-breed 11 33 Female
2 Hemangiopericytoma Elbow Local Irish Red and White Setter 10 35 Female
3 Hemangiopericytoma Carpus Local Boxer 11 30 Female
4 Hemangiopericytoma Thigh Local Labrador Retriever 11 37 Male
5 Hemangiopericytoma Forepaw Local Cross-breed 10 8 Female
6 Hemangiopericytoma Elbow Local Irish Red and White Setter 11 38 Female
7 Hemangiopericytoma Elbow Systemic Cross-breed 8 41 Male
8 Hemangiopericytoma Elbow, nasal Systemic Malinois 12 26 Female
9 Hemangiosarcoma Inguinal Local British Bulldog 6 29 Male
10 Spindle cell sarcoma, Hemangiosarcoma Perianal, thigh Systemic Schnauzer 11 55 Female
11 Spindle cell sarcoma Tongue Local Australian Shepherd 8 33 Female
12 Spindle cell sarcoma Foreleg Local Borzoi 9 50 Male
13 Spindle cell sarcoma Tarsus Local Flat-coated Retriever 10 27 Female
14 Spindle cell sarcoma Soft palate Local Labrador Retriever 7 35 Male
15 Spindle cell sarcoma Neck Local American Bulldog 12 34 Female
16 Soft tissue sarcoma Pelvis Local Labrador Retriever 9 24 Female
17 Soft tissue sarcoma Tarsal bones Local Golden Retriever 9 34 Male
18 Soft tissue sarcoma Perianal Local Labrador Retriever 12 35 Male
19 Fibrosarcoma Maxilla Local Magyar Vizsla 12 29 Male
20 Fibrosarcoma Hindleg Local Bernese Mountain 1 42 Male
21 Fibrosarcoma Mandible thorax Systemic Golden Retriever 9 25 Female
22 Osteosarcoma Humerus Local Cross-breed 11 19 Female
23 Osteosarcoma Humerus Local Hovawart 12 31 Female
24 Osteosarcoma Femur Local Labrador, Retriever 13 29 Female
25 Osteosarcoma Radius Local Leonberger 5 48 Female
26 Osteosarcoma Humerus Local Rottweiler 10 39 Female
27 Osteosarcoma Humerus heart Systemic Labrador Retriever 9 29 Female
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compared with control animals (median: 1.43 (0.68–2.97)
ng/ml) (Fig. 6). For the mast cell tumor subgroup, the AUC
was 74%. An Hsp70 serum concentration of 2.36 ng/ml (sen-
sitivity 67%, specificity 66%) was determined as a cut-off
value to detect canine mast cell tumors. The mixed group of
canine patients suffering from round cell tumors other than
mast cell tumors also significantly (p < 0.05) differed from
control animals (Fig. 6). A further subgroup analysis of dogs
with melanoma revealed elevated Hsp70 serum levels com-
pared with control animals as well; however, due to the rela-
tively small sample size (n = 5), the values did not reach sta-
tistical significance (p = 0.07, the Wilcoxon rank-sum test).
Discussion
In humans, the value of circulating exosomal and free Hsp70
as a diagnostic biomarker in serum and plasma has already
been demonstrated for different tumor entities (Breuninger
et al. 2014). Presently, there are two main pathways for
Hsp70 to be released into the circulation. Hsp70 can originate
from dying cells as a free protein, and it may be actively
released in lipid microvesicles, such as exosomes, by viable
malignantly transformed cells (DeMaio 2011; Gastpar et al.
2005; Pockley et al. 2014; Cordonnier et al. 2017). High in-
tracellular Hsp70 levels in human tumors are associated with
elevated Hsp70 levels in the circulation (Gunther et al. 2015).
The purpose of this study was to examine whether extracellu-
lar Hsp70, as determined by the lipHsp70 ELISA, could also
serve as a useful tool for tumor detection in canine patients.
Studies with domestic dogs as model organisms are of great
value for translational medicine, because dogs cohabitate with
their owners in the same (clean but not completely germ-free)
environment, are kept until reaching an old age, receive a high
level of healthcare, show a high genetic diversity, and sponta-
neously develop tumors in the same way as humans (Rowell
et al. 2011; Grosse et al. 2014). All pet dogs included in this
study developed spontaneous tumors of different entities.
Compared with humans (Breuninger et al. 2014), the
mean Hsp70 serum values of dogs were slightly lower.
No significant correlations of the Hsp70 serum concen-
trations were found regarding weight, age, gender,
breed, and pedigree of the dogs. Although Hsp70 levels
did not differ significantly in humans, plasma Hsp70
levels were always slightly lower than in serum. In
dogs, Hsp70 levels in the plasma were significantly
lower compared with those of serum. The reasons for
these differences have not yet been elucidated. One
might speculate that due to generally lower Hsp70
levels in dogs, the negative effect of the anti-coagulant
in plasma might be more pronounced in dog plasma
samples compared with human plasma samples.
Table 3 Characteristics of dogs diagnosed with epithelial tumors
# Diagnosis Tumor location Extension Breed Age Weight (kg) Gender
1 Anal gland carcinoma Anal sac Local Cross-breed 7 37 Male
2 Anal gland carcinoma Anal sac Local Cross-breed 9 25 Male
3 Anal gland carcinoma Anal sac Local Border Collie 10 26 Male
4 Anal gland carcinoma Anal sac Local Labrador Retriever 10 27 Male
5 Anal gland carcinoma Anal sac Local Anatolian Shepherd 10 26 Male
6 Anal gland carcinoma Anal sac Systemic Australian Shepherd 12 23 Male
7 Adenocarcinoma Nasal cavity Local Pug 9 11 Female
8 Adenocarcinoma Nasal cavity Local Fox Terrier 8 10 Male
9 Adenocarcinoma Nasal cavity Local Cross-breed 12 17 Male
10 Carcinoma Nasal cavity Local Cross-breed 11 24 Male
11 Carcinoma Nasal cavity Local Golden Retriever 13 38 Male
12 Carcinoma Nasal cavity Systemic Springer Spaniel 14 21 Male
13 Carcinoma Nasal cavity neck Local Golden Retriever 13 31 Female
14 Thyroid carcinoma Neck Local Kerry Blue Terrier 13 16 Female
15 Thyroid carcinoma Neck Local West Highland White Terrier 6 10 Male
16 Thyroid carcinoma Neck Local Labrador Retriever 12 37 Male
17 Salivary gland carcinoma Neck Local Portuguese Podenco 11 7 Female
18 Prostate carcinoma Prostate Local Bergamasco Shepherd 11 35 Male
19 Squamous cell carcinoma Tongue Local Appenzeller Sennenhund 13 50 Female
20 Squamous cell carcinoma Toe Systemic Labrador Retriever 12 21 Male
21 Basal cell carcinoma Nose Local Parson Russell Terrier 8 27 Male
22 Leydig cell tumor Testicle Local Border Terrier 12 31 Male
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As shown for human serum and plasma samples, up to
three repeated freezing/thawing cycles of the canine sera
did not significantly impact the Hsp70 concentrations as
assessed by the lipHsp70 ELISA. However, due to prob-
lems in protein stability, more than three freezing/thawing
cycles of the serum resulted in significantly lower Hsp70
concentrations in humans and dogs. As previously shown
by our group, Hsp70 tended to spontaneously form self-
aggregates (Stangl et al. 2018) that could negatively affect
the results of the lipHsp70 ELISA due to its oligomeriza-
tion domain.
As already demonstrated for human blood samples, a mas-
sive food intake (one-third of the daily ration) before blood
donation did not influence the Hsp70 levels measured with the
Table 4 Characteristics of dogs diagnosed with round cell tumors
# Diagnosis Tumor location Extension Breed Age Weight (kg) Gender
1 Mast cell tumor Nasal cavity Local Berger de Pyrenees 13 7 Female
2 Mast cell tumor Nasal cavity Local Magyar Vizsla 8 27 Male
3 Mast cell tumor Skin Local Labrador Retriever 12 31 Male
4 Mast cell tumor Rhinarium Local Jack Russel Terrier 12 12 Male
5 Mast cell tumor Abdomen Local Schnauzer 10 29 Female
6 Mast cell tumor Skin Local Bernese Mountain 10 41 Female
7 Mast cell tumor Thorax, thigh, ear Systemic Pug 9 7 Female
8 Mast cell tumor Shoulder, thorax, tarsus Systemic Golden Retriever 8 25 Female
9 Mast cell tumor Ear, scapula, thorax, thigh Systemic Greater Swiss Mountain 7 46 Female
10 Mast cell tumor Shoulder Local Cross-breed 12 27 Female
11 Mast cell tumor Nose Local Boxer 7 36 Male
12 Mast cell tumor Thoracic wall Systemic Labrador Retriever 8 25 Male
13 T cell lymphoma Mandible, lip Local Maltese 13 3 Male
14 T cell lymphoma Jejunum, liver, spleen Local Greyhound 9 5 Male
15 Plasmocytoma Rectum Local Cross-breed 13 30 Male
16 Follicular lymphoma Mandibular lymph nodes Local Maltese 7 4 Male
17 B cell lymphoma Liver, spleen Systemic Cross-breed 14 24 Female
18 B cell lymphoma Multicentric Systemic Golden Retriever 7 39 Male
19 Amelanotic melanoma Lip Local Golden Retriever 15 27 Female
20 Amelanotic melanoma Mandible Local Hovawart 12 33 Female
21 Amelanotic melanoma Gingiva, lung Systemic Poodle 9 22 Male
22 Malignant melanoma Mandible, oral mucosa Local Boxer 15 30 Female
23 Malignant melanoma Maxilla, orbital cavity Local Prague Ratter 14 3 Male
24 Malignant histiocytosis Popliteal lymph node, liver, lung Systemic Bernese Mountain 4 47 Male
25 Malignant histiocytosis Humerus, ulna, lung, liver, spleen Systemic Rottweiler 5 48 Male
Fig. 5 Comparative analysis of Hsp70 serum concentrations as
determined by the lipHsp70 (a) and R&D (b) ELISA in control and
tumor-bearing pet dogs. Serum samples were taken from a total of 112
dogs of different breeds: healthy control dogs (Ctrl: n = 38), dogs with
mesenchymal tumors (Mes:, n = 27), dogs with epithelial tumors (Epi:
n = 22), and dogs with round cell tumors (Rdc: n = 25). Tables 1, 2, 3,
and 4 summarize characteristics of the dog patients. Lines inside the box
plots show the median value, upper and lower boundaries indicate the
25th and 75th percentile, and whiskers indicate highest and lowest value
within 1.5 IQR, respectively. **p < 0.01
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lipHsp70 ELISA. This was an important prerequisite for med-
ical studies in pet animals.
To the best of our knowledge, Hsp70 serum concentra-
tions have never been investigated in dogs as a tumor
biomarker. Our study showed that circulating Hsp70
levels were higher in tumor-bearing dogs compared with
control animals. Especially round cell tumors, a heteroge-
neous group of tumors consisting of hematological malig-
nancies, including mast cells, plasma cells, lymphocytes,
histiocytes, and melanomas (Raskin and Meyer 2016) ex-
hibited significantly elevated Hsp70 serum levels.
Therefore, we proposed circulating Hsp70 as a potential
diagnostic tumor biomarker for dogs with round cell tu-
mors. A sub-classification of this tumor type revealed the
highest Hsp70 concentrations in dogs with mast cell tu-
mors. Hsp70 serum concentrations in dogs with melano-
ma were also found to be elevated compared with healthy
control animals, but the data were not statistically signif-
icant due to the relatively low number of animals.
Canine patients with mesenchymal and epithelial tumors
did not show significantly increased Hsp70 serum concentra-
tions compared with healthy animals. Decreased intracellular
Hsp70 concentrations were very unlikely to explain this find-
ing, because Western blot analysis showed an equally strong
Hsp70 expression in canine round cell and mesenchymal tu-
mor cell lines. Therefore, we speculated that round cell tumors
could have a higher capacity to release Hsp70, as a free mol-
ecule or in exosomes, into the bloodstream compared with
solid mesenchymal or solid epithelial tumors. Differences in
the total tumor burden could also provide an explanation for
the lower Hsp70 concentrations in the circulation of these
tumor entities. In tumor mouse models (Bayer et al. 2014) as
well as in human patients with NSCLC (Gunther et al. 2015),
the tumor volume correlated with serum Hsp70 levels.
However, this question was not addressed in the present study
as the tumor volumes of the dogs were not determined. Future
studies with larger cohorts of canine patients and different
tumor volumes are necessary to define the minimal volume
of tumors that is detectable by elevated Hsp70 serum levels in
dogs. Furthermore, kinetic measurements of the Hsp70 serum
levels may also be useful for monitoring therapy outcome by
minimally invasive methods in canine patients.
Funding information This work was supported by the following grants:
Deutsche Forschungsgemeinschaft DFG (SFB824/3), DFG (STA
1520/1-1), BMBF (Innovative Therapies (01GU0823), BMBF
Kompetenzverbund Strahlenforschung (02NUK038A), BMWi (AiF
ZF4320102CS7; ZF4320104AJ8).
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Akerfelt M, Morimoto RI, Sistonen L (2010) Heat shock factors: integra-
tors of cell stress, development and lifespan. Nat Rev Mol Cell Biol
11(8):545–555
Asling J, Morrison J, Mutsaers AJ (2016) Targeting Hsp70 and Grp78 in
canine osteosarcoma cells in combination with doxorubicin chemo-
therapy. Cell Stress Chaperones 21(6):1065–1076
Bayer C, Liebhart ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht
HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ,
Multhoff G (2014) Validation of hsp70 as a tumor-specific biomark-
er for monitoring the outcome of radiation therapy in tumor mouse
models. Int J Rad Oncol Biol Phys 88(3):694–700
Breuninger S, Erl J, Knape C, Gunther S, Regel I, Rödel F, Gaipl US,
Thorsteinsdottir J, Giannitrapani L, Dickinson AM, Multhoff G
(2014) Quantitative analysis of liposomal heat shock protein 70
(Hsp70) in the blood of tumor patients using a novel LipHsp70
ELISA. J Clin Cell Immunol 5:5
Chu RM, Sun TJ, Yang HY,WangDG, LiaoKW, Chuang TF, Li CH, Lee
WC (2001) Heat shock proteins in canine transmissible venereal
tumor. Vet Immunol Immunopathol 82(1–2):9–21
Ciocca DR, Calderwood SK (2005) Heat shock proteins in cancer: diag-
nostic, prognostic, predictive, and treatment implications. Cell
Stress Chaperones 10(2):86–103
Cordonnier M, Chanteloup G, Isambert N, Seigneuric R, Fumoleau P,
Garrido C, Gobbo J (2017) Exosomes in cancer theranostic: dia-
monds in the rough. Cell Adhes Migr 11(2):151–163
Daugaard M, Rohde M, Jäättelä M (2007) The heat shock protein 70
family: highly homologous proteins with overlapping and distinct
functions. FEBS Lett 581(19):3702–3710
DeMaio A (2011) Extracellular heat shock proteins, cellular export ves-
icles, and the stress observation system: a form of communication
during injury, infection, and cell damage. It is never known how far a
controversial finding will go! Dedicated to Ferruccio Ritossa. Cell
Stress Chaperones 16:235–249
Fig. 6 Comparative analysis of Hsp70 serum concentrations as
determined by the lipHsp70 ELISA in dogs with mast cell tumors (Mct)
and other round cell tumors. Within the group of patients with round cell
tumors, dogs with mast cell tumors (Mct: n = 12) showed the highest
Hsp70 serum concentrations followed by all other round cell tumor sub-
types (Rdc without Mct: n = 13). Hsp70 serum levels of Mct and other
Rdc were significantly higher than those of healthy controls. Lines inside
the box plots show themedian value, upper and lower boundaries indicate
the 25th and 75th percentile, and whiskers indicate highest and lowest
value within 1.5 IQR, respectively. *p < 0.05
7Hsp70 serum levels in pet dogs—a potential diagnostic biomarker for spontaneous round cell tumors 977
Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA,
Multhoff G (2005) Heat shock protein 70 surface-positive tumor
exosomes stimulate migratory and cytolytic activity of natural killer
cells. Cancer Res 65(12):5238–5247
Grosse N, van Loon B, Rohrer Bley C (2014) DNA damage response and
DNA repair–dog as a model? BMC Cancer 14:203
Gunther S, Ostheimer C, Stangl S, Specht HM, Mozes P, Jesinghaus M,
Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G (2015)
Correlation of Hsp70 serum levels with gross tumor volume and
composition of lymphocyte subpopulations in patients with squa-
mous cell and adeno non-small cell lung cancer. Front Immunol 6:
556
Hantschel M, Pfister K, Jordan A, Scholz R, Andreesen R, Schmitz G,
Schmetzer H, Hiddemann W, Multhoff G (2000) Hsp70 plasma
membrane expression on primary tumor biopsy material and bone
marrow of leukaemic patients. Cell Stress Chaperones 5(5):438–442
Hartl FU (1996) Molecular chaperones in cellular protein folding. Nature
381(6583):571–579
Horvath I, Multhoff G, Sonnleitner A, Vigh L (2008) Membrane-
associated stress proteins: more than simply chaperones. Biochim
Biophys Acta 1778(7–8):1653–1664
Hunt C, Morimoto RI (1985) Conserved features of eukaryotic hsp70
genes revealed by comparison with the nucleotide sequence of hu-
man hsp70. Proc Natl Acad Sci U S A 82(19):6455–6459
Kumaraguruparan R, Karunagaran D, Balachandran C, Murali Manohar
B, Nagini S (2006) Of human and canines: a comparative evaluation
of heat shock and apoptosis-associated proteins in mammary tu-
mours. Clin Chim Acta 365(1–2):168–176
Lindquist S, Craig EA (1988) The heat shock proteins. Annu Rev Genet
22:631–677
Multhoff G, Botzler C, Wiesnet M, Müller E, Meier T, Wilmanns W,
Issels RD (1995) A stress-inducible 72-kDa heat-shock protein
(HSP72) is expressed on the surface of human tumor cells, but not
on normal cells. Int J Cancer 61(2):272–279
Ostermann J, Voos W, Kang PJ, Craig EA, Neupert W, Pfanner N (1990)
Precursor proteins in transit through mitochondrial contact sites in-
teract with hsp70 in the matrix. FEBS Lett 277(1–2):281–284
Pockley AG, Henderson B, Multhoff G (2014) Extracellular cell stress
proteins as biomarkers of human diseases. Biochem Soc Trans
42(6):1744–1751
Qiu XB, Shao YM, Miao S, Wang L (2006) The diversity of the DnaJ/
Hsp70 chaperones. Cell Mol Life Sci 63(22):2560–2570
Radons J, Multhoff G (2005) Immunostimulatory functions of
membrane-bound and exported heat shock protein 70. Exerc
Immunol Rev 11:17–33
Raskin R, Meyer DJ (2016) General Categories of Cytologic
Interpretation. In: Canine and feline cytology: a color atlas and in-
terpretation guide, 3rd edn. Elsevier/Saunders, St. Louis, MO, pp
16–33
Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jäättelä M
(2005)Members of the heat-shock protein 70 family promote cancer
cell growth by distinct mechanisms. Genes Dev 19(5):570–582
Romanucci M, Marinelli A, Sarli G, Della Salda L (2006) Heat shock
protein expression in canine malignant mammary tumors. BMC
Cancer 6:171
Rowell JL, McCarthy DO, Alvarez CE (2011) Dog models of naturally
occurring cancer. Trends Mol Med 17(7):380–388
Selvarajah GT, Bonestroo FA, Kirpensteijn J, KikMJ, van der Zee R, van
Eden W, Timmermans-Sprang EP, Slob A, Mold JA (2013) Heat
shock protein expression analysis in canine osteosarcoma reveals
HSP60 as a potentially relevant therapeutic target. Cell Stress
Chaperones 18(5):607–622
Shalgi R, Hurt J, Lindquist S, Burge C (2014) Widespread inhibition of
posttranscriptional splicing shapes the cellular transcriptome follow-
ing heat shock. Cell Rep 7(5):1362–1370
Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I (2011) Targeting
membrane heat shock protein 70 (Hsp70) on tumors by cmHsp70.1
antibody. Proc Natl Acad Sci U S A 108(2):733–738
Stangl S, Tei L, De Rose F, Reder S, Martinellei J, Sievert W, Shevtsov
M, Öllinger R, Rad R, Schwaiger M, D’Alessandria C, Multhoff G
(2018) Preclinical evaluation of the Hsp70 peptide tracer TPP-
PEG24-DFO[89Zr] for tumor-specific PET/CT imaging. Can Res
78(21):6268–6281
Villiers E, Ristic J, Blackwood DL (2016) BSAVA manual of canine and
feline clinical pathology, 3rd edn. JohnWiley& Sons, Hoboken, NJ,
pp 409–426
Wegele H, Müller L, Buchner J (2004) Hsp70 and Hsp90-a relay team for
protein folding. Rev Physiol Biochem Pharmacol 151:1–44
Whitley D, Goldberg SP, Jordan WD (1999) Heat shock proteins: a re-
view of the molecular chaperones. J Vasc Surg 29(4):748–751
Withrow SJ, Vail DM, Page RL (2012) Withrow & MacEwen’s small
animal clinical oncology, 5th edn. Elsevier/Saunders, St. Louis,MO,
pp 117–130
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
978 L. Salvermoser et al.
